Aqumen Biopharmaceuticals aqumen.jp


Public list: Pharma Startups (4743) Eye Health (701)

The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degeneration (AMD). and iii)A0006 . Company is in negotiations to acquire rights to a Phase II program by year end 2007. The following diagram summarizes the important existing and anticipated clinical development milestones for each of the programs as they relate to their respective targeted applications:

The company's current portfolio of compounds and technologies in the development pipeline includes: i) A0001, Ophthalmic Dye for Retinal Surgery ii) A0003, treatments for Age-related Macular Degeneration (AMD). and iii)A0006 . Company is in negotiati...Show all

Company (Alive / Active)

Phone:

Fax:

Collabo Station II 604
3-1-1 Maidashi, Higashi-ku
Japan

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Aqumen Biopharmaceuticals $0M Apr 19, 2019
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Aqumen Biopharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Corthera

San Mateo, California, United States
AcquiredCorthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for the treatment of acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com. Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodil...Show allLogin to see details

CoMentis

South San Francisco, California, United States
Alive / ActiveCoMentis is focused on developing drugs to treat various central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company covers the research and development spectrum from initial drug design through manufacturing and clinical trials.Login to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)